Objectives: To describe the clinical presentation, MRI findings and outcome in dogs with eosinophilic meningoencephalitis of unknown origin.
INTRODUCTION
Eosinophilic meningoencephalitis is diagnosed in humans and animals when neurological disease is associated with an eosinophilic pleocytosis (Williams et al. 2008) . In humans, an eosinophilia of greater than 10% of the total white blood cell count in the CSF is often used as a criterion for the diagnosis of eosinophilic meningoencephalitis (Kuberski 1981 , Graeff-Teixeira et al. 2009 ). Eosinophilic meningoencephalitis in dogs can be associated with infectious and non-infectious causes. Infectious causes in dogs include Neospora caninum and, less often, Toxoplasma gondii (Bennett et al. 1997 , Smith-Maxie et al. 2008 ).
Other infectious causes include Angiostrongylus vasorum, Prototheca species Crytococcus species, canine distemper virus, rabies and bacterial encephalitis (Smith-Maxie et al. 2008 , Windsor et al. 2009 ). Non-infectious causes of eosinophilic meningoencephalitis include neoplasia, infarction, shunt placement and trauma (Smith-Maxie et al. 2008 , Windsor et al. 2009 ).
If no infectious or systemic causes have been identified, the term eosinophilic meningoencephalitis of unknown origin (eosinophilic MUO) can be used. Eosinophilic MUO is considered a rare condition, with only 30 canine cases reported to date, and is now considered part of the canine non-infectious meningoencephalitides spectrum (Bennett et al. 1997 , Salvadori et al. 2007 , Smith-Maxie et al. 2008 , Williams et al. 2008 , Henke et al. 2009 , Windsor et al. 2009 , Granger et al. 2010 , Olivier et al. 2010 , Lowrie et al. 2013 . Eosinophilic MUO affects multiple breeds and is suggested to be more common in young, male, large-breed dogs. Reported clinical signs are variable and include mentation changes, ataxia, visual deficits, cervical hyperaesthesia and seizures (Bennett et al. 1997 , Salvadori et al. 2007 , Smith-Maxie et al. 2008 , Williams et al. 2008 , Henke et al. 2009 , Windsor et al. 2009 , Granger et al. 2010 , Olivier et al. 2010 . Descriptions of pathological findings and MRI characteristics of eosinophilic MUO are limited and range from severe and diffuse eosinophilic meningitis with infiltration of the superficial cortex to multi-focal granulomatous intra-axial mass lesions associated with eosinophilic infiltration of the parenchyma (Bennett et al. 1997 , Salvadori et al. 2007 , Henke et al. 2009 , Olivier et al. 2010 . Eosinophilic MUO is thought to be an immune-mediated condition, although the pathogenesis remains unknown (DortaContreras & Reiber 1998 , Williams et al. 2008 . Treatment typically consists of immunosuppressive doses of corticosteroids, medication for potential infectious causes and supportive care. Reports of response to immunosuppressive therapy are limited, with some dogs experiencing the resolution of clinical signs with corticosteroid treatment, while others rapidly succumb despite aggressive treatment and supportive care (Bennett et al. 1997 , Salvadori et al. 2007 , Smith-Maxie et al. 2008 , Williams et al. 2008 , Henke et al. 2009 , Windsor et al. 2009 , Granger et al. 2010 , Olivier et al. 2010 . In 15 to 20% of reported cases diagnosed with eosinophilic meningoencephalitis, the clinical presentation, imaging findings and outcomes were potentially influenced by a possible infectious aetiology, meaning these cases may not have been truly "idiopathic" (Smith-Maxie et al. 2008 , Williams et al. 2008 , Henke et al. 2009 ). Given the diverse clinical and imaging findings, the aims of this study were to better describe the clinical presentation, diagnostic test results, imaging findings and treatment outcomes in dogs with eosinophilic MUO without evidence of infectious disease.
MATERIALS AND METHODS

Case selection and medical records review
The electronic medical records of the University of London Royal Veterinary College (RVC) Small Animal Referral Hospital and Ghent University (GU) were searched to identify dogs with suspected eosinophilic MUO that were diagnosed between January 1, 2000 and April 1, 2017. Search terms used included "eosinophilic meningoencephalitis," "eosinophilic meningitis," "eosinophilic pleocytosis," "eosinophilia," "MUA," "MUO," "meningoencephalitis of unknown aetiology/etiology/origin" and various combinations of these terms. Dogs were included if they had: (1) complete medical records available, (2) a complete neurological examination suggestive of a focal or multifocal intracranial neuroanatomical localisation, (3) eosinophilic pleocytosis on cerebrospinal fluid (CSF) analysis (Total nucleated cell count [TNCC] >5 cells/mm 3 of CSF, >10% eosinophils on a 100 cell differential count) and (4) MRI of the brain (Granger et al. 2010) . Dogs were excluded if: (1) clinical records or imaging studies were incomplete or not available for review, (2) meningomyelitis without clinical signs of intracranial involvement was diagnosed or (3) if eosinophilic pleocytosis was not found on CSF analysis (Bosch & Oehmichen 1978 , Windsor et al. 2009 ). Information obtained from medical records included signalment, duration of clinical signs before diagnosis (time to presentation), treatment received before referral, general physical examination and neurological examination findings, neuroanatomical localisation and results of diagnostic tests including complete blood count (CBC), serum biochemistry profile, ancillary tests for infectious agents and results of cisternal CSF analysis. Dogs were classified as small (<10 kg), medium (10 kg to 30 kg) or large (>30 kg) breeds based on body weight (Cardy et al. 2015) . Possible categories of neuroanatomical localisation included diffuse forebrain, multi-focal brain, central vestibular system or cranial nerves. The study was approved by the RVC Ethics and Welfare committee (protocol number URN 2017 1684-3).
Ancillary diagnostic tests
For cisternal CSF analysis, TNCC, total protein (TP) concentration and nucleated cell differential count were recorded. TNCC was considered normal if the TNCC was less than 5 cells/mm 3 (Di Terlizzi & Platt 2009 , Dewey & da Costa 2016 T2-weighted (T2W) [repetition time (ms) (TR)/echo time (ms) (TE), 3000/120], T1-weighted (T1W) (TR/TE, 400/8) and fluid-attenuating inversion recovery (FLAIR) images of the entire brain in a sagittal, transverse and dorsal plane. The T1W images were acquired before and after intravenous administration of dose of 0·1 mg/kg paramagnetic contrast medium (gadoterate meglumine, Dotarem, Guerbet). Variables recorded were lesion localisation and distribution, presence of parenchymal or meningeal contrast enhancement, presence of mass effect (brain herniation, midline shift, flattening of gyri/sulci), T1W/T2W/FLAIR signal intensity of the cerebral grey matter and size of the cerebral sulci/subarachnoid spaces.
Treatment and follow-up
The specific treatment protocol was recorded for all dogs (corticosteroids with or without cytosine arabinoside). Following admission, all dogs underwent at least one daily general physical examination and neurological examination by a board-certified neurologist or a neurology resident during hospitalisation. Neurological examination results and response to treatment (improvement, deterioration or static) were recorded in the medical records until discharge. Following discharge, medical records were searched for re-examination or owner/vet communication to confirm if the dog was alive or dead and the current treatment as of April 1, 2017. For those dogs managed at their referring practices, the veterinary surgery was contacted directly (by TC) by telephone for a verbal update on neurological status and current treatment.
Statistical analysis
Data analysis was performed using a standard statistical software package (SPSS: Statistical Package for the Social Sciences 22·0·1, SPSS). Non-parametric data were described using median and range. Relationships between variables were investigated using Pearson correlation coefficient. Values of P<0·05 were considered significant. Survival was defined as time from diagnosis to death or euthanasia because of disease progression or time from diagnosis to last follow-up for dogs that were alive at time of data capture.
RESULTS
Signalment
Initial database searches identified 27 dogs from the RVC and four dogs from GU. Eleven dogs met the inclusion criteria (nine from the RVC and two from GU). Four dogs were small breed, four were medium-sized, and three were large breeds. Median bodyweight at presentation was 18·0 kg (range: 4·9 to 36·0 kg), and median age at presentation was 22·0 months (range: 7·6 to 92·0 months). Six dogs were male, of which two were neutered, compared with five females, of which one was neutered. There were nine breeds represented, including two flat-coated retrievers and two Welsh terriers (Table 1) . The 11 dogs included in the current study were predominantly younger, entire, large-breed dogs as previously reported. (Bennett et al. 1997 , Salvadori et al. 2007 , Smith-Maxie et al. 2008 , Williams et al. 2008 , Henke et al. 2009 , Windsor et al. 2009 , Granger et al. 2010 , Olivier et al. 2010 .
Clinical signs
Median duration of clinical signs before diagnosis was 24 days (range: 2 to 78 days). The most common reasons for presentation included one or more of the following neurological signs: behaviour changes (n=10), ataxia (n=6), seizures (n=2), suspected blindness (n=3) and head tilt (n=2). A single dog was referred for masticatory muscle atrophy and an inability to blink the left eye. Three dogs were treated with a dose of 0·35 to 1·8 mg/kg/ day oral prednisolone before referral for suspected otitis media/ interna or suspected MUO. Median duration of corticosteroid treatment was 16·5 days (range: 1 to 90 days) ( Table 1) .
Neurological examination
Mentation was classified as abnormal in 10 dogs, with all being described as mild to moderately obtunded. Seven dogs had ataxia affecting all limbs, and seven had proprioceptive deficits (Table 1) . Nine dogs had a reduced or absent menace response, and two had a reduced or absent pupillary light reflex (Table 1) . Two dogs presented with neurological signs consistent with a diffuse forebrain localisation, four with a multi-focal localisation, four with a central vestibular localisation and one with focal signs affecting the left trigeminal and left facial nerves (Table 1) .
Diagnostic findings
One dog had moderate neutrophilia measuring 24·5×10 9 /L (reference interval: 3·0×10 9 to 11·5×10 9 /L), suspected to be a result of chronic steroid treatment for presumed otitis interna/media. White blood cell counts of the remaining 10 dogs were within normal limits (reference interval: 6 to 17·1×10 9 /L). Nine dogs showed peripheral eosinophilia with a median cell number of 1·60×10 9 /L (range: 0·2×10 9 to 3·81×10 9 /L, reference interval: 0·0×10 9 /L to 1·3×10 9 /L), with all dogs having an increased proportion of eosinophils in the white blood cell count (Table 1) . Cisternal CSF analysis demonstrated an eosinophilic pleocytosis in all dogs with a median TNCC of 671 WBC/mm 3 (range: 6 to 5400 WBC/mm 3 , reference interval: <5 WBC/mm 3 ). The median differential cell count included 85% eosinophils (range: 12 to 95%, reference interval: <1%). CSF median TP concentration was 0·61 mg/dL (range: 0·23 to 1·06 mg/dL, reference interval: <25 mg/dL). There was a significant positive correlation between eosinophil percentage in the CBC and eosinophil percentage in the CSF (r=0·683, P=0·01). There was also a positive correlation between eosinophil numbers on CBC and the TNCC (r=0·618, P=0·032).
Serology and/or PCR analysis of CSF for T. gondii, N. caninum were available and negative in all 11 dogs. PCR of CSF for canine distemper virus was available and negative in three dogs. Five dogs were tested -and negative -for A. vasorum, E. canis, B. burgdorferi, A. phagocytophilum and A. platys with SNAP 4Dx ELISA (Idexx) , and serology for Cryptococcus species was negative in three dogs. A further eight dogs were negative for A. vasorum by Angio Detect (Idexx), and faecal analysis was normal in three dogs. All 11 dogs tested negative for Angiostongylus vasorum by one or more tests.
MRI findings
MR imaging was performed between 3 and 40 hours after admission. In 10 of the 11 dogs, images demonstrated a T1W iso/ hypointense to normal grey matter, T2W and FLAIR hyperintense signal affecting the cortical grey matter (Fig. 1A to C) . Cerebral sulci appeared grossly enlarged, with a reduction in the size of the cortical gyri (Fig 1A, C) . In all of these 10 dogs, the lesions were bilateral and symmetrical and confined to the cerebral cortex on MR images. T1W images retrieved after gadolinium contrast administration revealed diffuse contrast uptake affecting both the pachymeninges and leptomeninges in 10 dogs ( Fig  1D, Table 1 ). Abnormalities detected in the MRI studies were felt to be most consistent with diffuse meningitis and atrophy or necrosis of the cortical grey matter. In the remaining dog, there was marked masticatory muscle atrophy with regions of T2W and FLAIR hyperintensity within the masseter and temporalis muscles, which also showed moderate contrast uptake (Fig 2) . The left trigeminal nerve was T2W and FLAIR hyperintense compared with the right side and showed mild homogenous contrast enhancement (Fig 2) . There was also a left mandibular lymphadenopathy. Significant MRI abnormalities could not be detected in the left facial nerve.
Treatment
All dogs survived initial general anaesthesia for MRI, and then 10 dogs received a single intravenous dose of 0·3 to 0·5 mg/kg dexamethasone within hours of diagnosis. In eight dogs, initial dexamethasone treatment was followed by high-dose of 4 mg/kg/ day oral prednisolone therapy that was reduced after 48 hours (2 mg/kg/day). In two dogs, the initial starting dose of 2 mg/kg/ day oral prednisolone was and was reduced to 1 mg/kg/day after 48 hours. In one dog, the initial oral prednisolone dose was 1 mg/ kg/day until tests for Cryptococcus returned negative, at which time the oral prednisolone dose was increased to 2 mg/kg/day for 6 weeks before reducing the dose to 1 mg/kg/day. The final dog did not receive steroid therapy and died the day after diagnosis (Case 11, Table 1 ). Dogs typically remained on the same dose of oral prednisolone for 3 weeks, after which the dose was reduced by 50% depending on clinical progression. At the time of diagnosis, seven dogs received additional treatment with a dose of 50 mg/m 2 cytosine arabinoside, administered as subcutaneous injections every 12 hours for two consecutive days. Dogs that started cytosine arabinoside treatment received a second course 3 weeks after initial treatment, and treatment intervals were then typically extended by a week at each presentation depending on clinical progression. In eight dogs, a 14-day course of clindamycin was also provided (11 to 14 mg/kg twice a day) until Protozoal infectious disease tests returned negative.
Outcomes
Of the 11 dogs, 10 survived to discharge, and one dog died of respiratory arrest the day after presentation (Table 1) . One dog was euthanased as a result of disease progression at 31 days after diagnosis (Table 1) . Two dogs were lost to follow-up at 60 days and 732 days; both were alive and considered to be neurologically improved at that time. One of the dogs lost to follow-up was receiving a dose of 1·5 mg/kg/day oral prednisolone only , while the other dog was not receiving any immunosuppressive treatment (Table 1) . Median survival time was 762 days (Ranging from 31 to 3631 days). At the time of data capture, seven dogs were alive and had full follow-up information. Three dogs were considered to be neurologically normal, and three dogs were considered improved but with mild deficits in menace response. The dog with left-sided facial and trigeminal nerve deficits initially responded well to immunosuppressive treatment but relapsed after the first prednisolone dose reduction at 3 weeks, requiring a return to 2 mg/kg/day oral prednisolone, after which time it continued to improve (Table 1) . Of the seven dogs for which follow-up information was available, two were not receiving any immunosuppressive therapy, two dogs were receiving only 50 mg/ m 2 cytarabine arabinoside subcutaneous every 12 hours for two consecutive days) at 8-weekly intervals, two dogs were receiving a combination of 1 to 2 mg/kg/day oral prednisolone and cytarabine arabinoside, and one dog was receiving 0·5 mg/kg oral prednisolone every other day (Table 1) . Case 5 had repeat MRI and cisternal CSF sampling at 1173 days after diagnosis at the owner's request. Neurological examination was within normal limits, although the dog was felt by the owner to be slower to respond to commands and often seemed confused during everyday life. CSF reported a TNCC of zero and a protein level of 0·13 mg/dL (reference interval < 25 mg/dL). MRI findings included worsen-429 ing vetriculomegaly, further widening of the subarachnoid space, a reduction in size of the interthalamic adhesion and increased T2W hyperintense signal surrounding the cortical grey matter (Fig 3) . These findings were felt to be consistent with worsening diffuse meningitis and atrophy or necrosis of the cortical grey matter.
DISCUSSION
Eosinophilic MUO has been sporadically reported in dogs and, to date, no clear consensus has been reached on the clinical presentation and MRI findings, making effective diagnosis and treatment challenging (Bennett et al. 1997 , Salvadori et al. 2007 , Smith-Maxie et al. 2008 , Williams et al. 2008 , Henke et al. 2009 , Windsor et al. 2009 , Granger et al. 2010 , Olivier et al. 2010 .
Eosinophils are secretory cells that provide a host defence against parasites but also have the potential to modulate inflammatory responses by producing cytokines and can contribute to chronic inflammation in a wide range of tissues (Lilliehook et al. 2000) . Eosinophils differentiate from myeloid precursor cells and enter the circulation after maturation, where they last for only minutes to hours and are rapidly recruited in response to chemokines into target tissues or inflammatory sites where they can survive for up to 2 weeks (Young et al. 2006) . Eosinophils release neurotoxic proteins, such as eosinophilic cationic protein, major basic protein and eosinophil-derived neurotoxin, and also produce reactive oxygen and nitrogen metabolites, causing severe tissue damage (Oliveira & Lukacs 2003 , Temkin et al. 2004 ). In the brain, neurons and myelinated axons are highly susceptible to eosinophilic-induced neurotoxicity (Williams et al. 2008) .
Consistent with previous reports, the most common neurological examination findings included one or more of the following: mentation changes, seizures, proprioceptive deficits, visual deficits and reduced or absent menace response consistent with a diffuse forebrain neuroanatomic localisation (Bennett et al. 1997 , Salvadori et al. 2007 , Smith-Maxie et al. 2008 . Central vestibular lesions have only previously been reported in one case of eosinophilic MUO, but here, four dogs showed neurological signs consistent with a central vestibular localisation, including head tilt, nystagmus, mentation changes and vestibular ataxia (Henke et al. 2009 ). Although no lesions in the central vestibular system were detected on MRI in the current study, previously reported histopathological findings demonstrated an eosinophilic infiltrate throughout the brainstem and cerebellum, which could account for the observed central vestibular signs (Olivier et al. 2010) . Nine dogs had peripheral eosinophilia, and all dogs had an increased proportion of eosinophils in the CBC (Table 1) . This compares with previous reports in which 51% of dogs had a peripheral eosinophilia. CSF analysis in all dogs showed an eosinophilic pleocytosis and increased TP concentration consistent with previous reports. Case 2 is notable in that, although all values were within the inclusion criteria, the TNCC and differential cell count were lower than other cases (Table 1) . This dog is unique in that it had received a 90-day tapering dose of corticosteroids before diagnosis, and it is believed that the low TNCC, in comparison with the other cases, is reflective of a response to immunosuppressive corticosteroid treatment.
MRI findings have previously been reported in 16 dogs with presumed eosinophilic meningoencephalitis of unknown origin and were considered normal in six. Two dogs had bilateral, symmetrical cortical atrophy and diffuse meningeal contrast uptake (Salvadori et al. 2007 , Henke et al. 2009 , Windsor et al. 2009 ). In the current study, 10 dogs demonstrated a T2W and FLAIR hyperintense signal affecting the cortical grey matter; T1W iso/ hypointense to normal grey matter, with enlarged cerebral sulci; a reduction in cortical gyri; and diffuse meningeal contrast uptake (Fig 1) . These MRI findings are identical to previous case reports in which the accompanying histopathology was consistent with severe eosinophilic and macrophagic inflammation, resulting in diffuse meningitis and atrophy or necrosis of the cortical grey matter (Salvadori et al. 2007 , Henke et al. 2009 , Windsor et al. 2009 ). Based on the histopathological findings reported by other authors and MRI findings in the current study, it is suggested that the majority of dogs with eosinophilic MUO suffer from diffuse cerebrocortical meningitis and cortical (polio) encephalitis, which can be clearly identified on MRI (SmithMaxie et al. 2008 , Williams et al. 2008 , Henke et al. 2009 , Olivier et al. 2010 . Although no histopathology was available for dogs in the current study, it is thought that MRI findings are due to the migration of eosinophils via the meningeal vasculature into the meninges and cerebral cortex, leading to an inflammatory response and neuronal necrosis in the cerebral cortex (Bennett et al. 1997 , Smith-Maxie et al. 2008 . In other forms of non-infectious meningoencephalitides [granulomatous meningoencephalitis (GME), necrotising meningoencephalitis (NME), necrotising leukoencephalitis (NLE)], lesions reflect the types of lesion associated with each disorder, often with significant overlap between conditions (Talarico & Schatzberg 2010) . Consequently, MR images are rarely pathognomonic, with variables such as the presence or absence of necrosis, topographical distribution, mass effect and the level of meningeal contrast uptake, allowing some differentiation between diseases (Talarico & Schatzberg 2010 , Coates & Jeffery 2014 . GME, NLE and NME frequently produce multi-focal, asymmetrical, intra-axial lesions that variably affect grey and white matter. This is in contrast to MR images from the current study in which lesions were most often bilateral, symmetrical, limited to the cerebral cortex and associated with diffuse meningeal contrast uptake (Talarico & Schatzberg 2010 , Coates & Jeffery 2014 . Other potential differential diagnoses for the bilateral cortical changes noted on MRI could include storage diseases such as neuronal ceroid lipofuscinosis (Nakamoto et al. 2011) , canine cognitive dysfunction (Hasegawa et al. 2005) or cerebrocortical necrosis secondary to metabolic or nutritional abnormalities (Singh et al. 2005 , Dewey & da Costa 2016 . However, the signalment of dogs in the current study, normal biochemical test results, CSF analysis demonstrating an eosinophilic pleocytosis and the specific nature of the MRI findings were not felt to be consistent with alternate differential diagnoses.
The final dog in the current study had marked masticatory muscle atrophy, left facial nerve and trigeminal nerve dysfunction and an enlarged and contrast-enhancing left trigeminal nerve on MRI (Table 1, Fig 2) . There were also T2W and FLAIR hyperintense lesions within the muscle and mild patchy contrast uptake post-gadolinium administration on T1W images. Focal involvement of cranial nerves in dogs with eosinophilic MUO has previously been reported in a 4-year-old golden retriever and a 13-year-old German shepherd dog. As in the current study, both dogs reported in the literature were the oldest in their respective studies (Smith-Maxie et al. 2008 , Windsor et al. 2009 ). Atrophy and MRI changes of masticatory muscles have been reported with conditions causing a focal myositis or neuritis affecting the trigeminal nerve, including immune-mediated masticatory myositis, myositis or neuritis as a result of N. caninum, trauma or neoplasms. Serum biochemistry and tests for infectious agents were negative, making an infectious aetiology less likely. Further diagnostic tests that could have been performed to further exclude neoplastic or inflammatory/infectious differentials include muscle biopsy and histopathology, 2 M antibody testing and fine-needle aspirates of muscle or nerve (Cauduro et al. 2013 , Dewey & da Costa 2016 .
Due to the small sample size and lack of histopathology, it is challenging to draw robust conclusions on outcomes for dogs diagnosed with eosinophilic MUO. However, in the current study the outcome was good overall, with over 90% of dogs surviving to discharge and 75% of dogs, for which long-term follow-up was available, considered neurologically normal or markedly improved. It should be noted that for two dogs included in the survival analysis, the follow-up time from diagnosis was 60 days or less (Cases 3 and 8), which may potentially bias the analysis of median survival time and highlights the need for a larger sample size in studies of this type. One dog died because of disease progression, and a further two were euthanased as a result of persistent clinical signs, which is similar to previous reports in which 25% of dogs with eosinophilic MUO died or were euthanased because of the condition (Windsor et al. 2009 ). Only two of the seven dogs for which follow-up was available were not receiving any treatment, while the remaining five received long-term low doses of prednisolone, cytarabine arabinoside or a combination of the two. While it is challenging to make direct comparisons with treatment protocols used in other forms of MUO, the outcome data in this study compare favourably with other non-infectious meningoencephalitides for which mortality rates are as high as 26% in the first week following diagnosis (Cornelis et al. 2016a,b) . The good response to long-term immunosuppressive drugs observed in many dogs with eosinophilic MUO, and no evidence of infectious disease, further supports an underlying immune-mediated condition that may be affecting cortical neurons (Windsor et al. 2009 , Talarico & Schatzberg 2010 . It is of note that in the single dog that had follow-up MRI 1173 days after diagnosis, the MRI findings had shown a significant progression, including worsening cortical atrophy and ventriculomegaly, despite a normal CSF sample (Fig 3) . This suggests that the cortical damage caused by eosinophilic MUO is permanent and potentially progressive despite effective treatment of the disease, as determined by CSF sampling. This study is limited by its retrospective nature and the small number of cases, preventing robust conclusions being drawn on outcomes and prognostic indicators for dogs with eosinophilic MUO. To date, no dogs have been available for post mortem examination. A key area of future work is to obtain histopathology to corroborate MRI findings and gain a better understanding of the underlying pathology of eosinophilic MUO.
The majority (83%) of eosinophilic MUO cases are presented as a severe diffuse cerebrocortical meningitis and cortical encephalitis, which can be clearly identified on MRI. A total of 75% of dogs in this study had a favourable response to immunosuppressive therapy in the medium to long term. These distinct MRI findings may serve as an aid in the diagnosis of eosinophilic MUO in dogs.
